BeOne Medicines valuation
$413.26Change from previous close: +0.48%Absolute change: +$1.97
Valuation
The P/E ratio is 52.7. The average price target of 27 analysts is $469.23.
Data as of November 17, 2026
BeOne Medicines compared with similar companies
BeOne Medicines's P/E (trailing 12 months): 52.7, +35% against the median of a group of 6 similar companies (39.2).
| Metric | BeOne Medicines | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 52.7 | 39.2 | 24.0 – 50.9 | High |
| Forward P/E | 38.4 | 15.2 | 13.7 – 33.5 | High |
| EV/EBITDA | 32.6 | 20.8 | 15.8 – 24.6 | High |
| Price/book | 8.06 | 7.12 | 4.39 – 14.1 | Middle |
| Price/sales | 7.11 | 9.44 | 6.15 – 17.1 | Middle |
| Gross margin | 89.4% | 59.8% | 23.4% – 80.8% | High |
| Operating margin | 17.8% | 17.8% | -68.1% – 31.2% | Middle |
| Net margin | 13.9% | 6.7% | -19.9% – 27.1% | Middle |
| ROE | 18.4% | -0.2% | -28.0% – 14.2% | High |
| Debt/equity | 0.35 | 0.35 | 0.02 – 0.73 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $46.98B
- Enterprise value
- $43.26B
- PEG
- 0.73
- EV/revenue
- 6.55
Profitability and growth
- ROA
- 8.4%
- ROIC
- 62.6%
- Revenue growth (year over year)
- 33.8%
- Earnings growth (year over year)
- 212.5%
Financial health
- Total cash
- $5.78B
- Total debt
- $2.06B
- Current ratio
- 3.55
- Quick ratio
- 3.10
- Piotroski F-Score
- 7.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $469.23
- Median price target
- $468.62
- High price target
- $561.30
- Low price target
- $400.00
- Analysts with a price target
- 27
- Consensus
- Strong buy
- Forward EPS
- $10.72
- EPS estimate, current year
- $9.87
Shares and trading
- Beta
- 0.63
- Average volume
- 400.19K
- Shares outstanding
- 105.38M
- Float
- 81.36M
- Institutional ownership
- 34.6%
- Insider ownership
- 17.3%
- Short interest (% of float)
- 2.0%
- Short ratio (days)
- 4.32
